IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION
Inventor(s): Manzer Durrani, et al.)	Art Unit: 1614
Application No.: 10/579,088	Ś	
Filed: November 11, 2004)	Examiner: Not Yet Assigned
Title Alpha 1-Antitrypsin Compositions and Treatmer Methods Using Such Compositions	nt)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop ____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			
		(1)	It is being filed within 3 months continued prosecution application OR	s of the application filing date and is other than a on under § 1.53(d)
		(2)	It is being filed within 3 months	s of entry of a national stage
	\boxtimes	(3)		date of the first Office Action on the merits
		(4)		ng of a first Office Action after the filing of a request $r \S 1.114$.
☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) the filing date of a national application; (2) three months beyond the date of e set forth in §1.491 in an international application; or (3) the mailing date emerits, but before the mailing date of the earlier of a final office action un allowance under §1.311, then:			onths beyond the date of entry of the national stage as n; or (3) the mailing date of a first Office action on the	
		a certif	ication as specified in §1.97(e) is	provided below; or
			f \$180.00 as set forth in \$1.17(p) nt of other papers filed together w	is authorized below, enclosed, or included with the with this statement.
37 C.F.R. §1.97(d). If this statement is being filed after the action under §1.113 or a notice of allowance under §1.311,				
	A.	a certif	ication as specified in §1.97(e) is	completed below; and
	B.	a petition herewit		testing consideration of this statement is submitted
	C.		f \$130.00 as set forth in §1.17(i)(nt of other papers filed together w	 is authorized below, enclosed, or included with the vith this statement.
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 07-1700 (Docket No. 123887-182052).			
				Respectfully submitted, GOODWIN PROCTER LLP
Dated:		April 21	, 2008	By: Jeffery Bernhardt, Reg. No. 54,997
Goodw	in Proct	er LLP		-

Goodwin|Procter LLP 135 Commonwealth Drive Menlo Park, CA 94025 (650) 752-3100 Customer No. 77845